PNH Diagnosis & Treatment

 

*Adapted from Parker et al. Blood.  2005.

Evaluate high-risk patient populations for PNH.

Early diagnosis drives effective PNH management

Diverse PNH symptomatology may complicate and delay diagnosis. Disease progression resulting from serious clinical sequelae reinforces the importance of early diagnosis. Accordingly, the current availability of an effective PNH treatment option warrants testing appropriate patients. Click below to learn more about the PNH Diagnostic Pathway.
Learn more

New Clinical Cytometry Society guidelines

Now you can more accurately identify and monitor PNH in your practice. Click here to download the full guidelines.


Do you have high-risk patients in your practice?

Hear how a physician from a large network practice implemented the PNH Diagnostic Pathway. Click here



Treatment Options

Treatments include the first humanized monoclonal antibody (MAb) therapy approved for the long-term management of PNH, palliative therapies like transfusions and steroids, and bone marrow transplantation (BMT).

Monoclonal Antibody Therapy

Palliative Therapies

Bone Marrow Transplantation


References: 1.Parker C, Omine M, Richards S, et al; for International PNH Interest Group. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood. 2005;106:3699-3709. 2. Sugimori C, Chuhjo T, Feng X, et al. Minor population of CD55-CD59- blood cells predicts response to immunosuppressive therapy and prognosis in patients with aplastic anemia. Blood. 2006;107:1308-1314.